Kimball Electronics (KE) Proxy filing summary

Executive summary

• Fiscal year 2026 marked a significant transformation, including the 65th anniversary, facility expansions, and the acquisition of Helvoet Polymer Technologies, enhancing medical manufacturing capabilities and global reach.

• Revenue reached $1.4 billion, with medical sales up year-over-year, adjusted operating income margin at 4.6%, and $72 million in operating cash flow.

• Debt was reduced to $117 million, the lowest in four years, and $12 million was returned to shareholders via share repurchases.

• A phased rebranding to Kimball Solutions is underway, with a shareholder vote to approve the name change.

Voting matters and shareholder proposals

• Four proposals: election of three directors, ratification of Deloitte & Touche LLP as auditor, advisory vote on executive compensation, and approval of the corporate name change.

• Board recommends voting FOR all proposals.

• Shareholders of record as of September 14, 2026, are eligible to vote at the November 13, 2026 meeting.

Board of directors and corporate governance

• Board is classified into three tiers, promoting independence, stability, and long-term focus.

• Majority of directors are independent, with an average tenure of 8.9 years.

• Board committees: Audit, Nominating and ESG, and Talent, Culture & Compensation, all chaired by independent directors.

• Board qualifications emphasize executive, industry, financial, governance, and ESG expertise.

• Shareholder rights include single-class voting, proxy access, and the ability to call special meetings.